Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine
Open Access
- 5 November 2017
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-9
Abstract
Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths worldwide. Additionally, there is concern for overdiagnosis and overtreatment of PC. Thus, selection of an appropriate candidate for active surveillance as well as more accurate and less invasive tools for monitoring advanced PC is required. Circulating tumor cells (CTCs) have emerged as a liquid biopsy tool; there have been several reports on its role, technologies, and applications to various cancers, including PC. Liquid biopsy using CTCs has been gaining attention as a minimal invasive tool for investigation of biomarkers and for prognosis and assessment of response to therapies in patients with PC. Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points. CTC analysis enables detection of genomic alterations, which is drug-targetable, and it is a potential tool for monitoring response to therapeutic agents in patients with PC. This review focuses on the characteristics, technologies for analysis, and advantages and disadvantages of CTCs as a liquid biopsy tool and their application in PC. Finally, we propose future directions of CTCs.Keywords
Funding Information
- National Cancer Center (1510170-3)
This publication has 110 references indexed in Scilit:
- Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for SurvivalEuropean Urology, 2014
- Detection of circulating tumor cells in different stages of prostate cancerJournal of Cancer Research and Clinical Oncology, 2013
- Computational Analysis of Microfluidic Immunomagnetic Rare Cell Separation from a Particulate Blood FlowAnalytical Chemistry, 2012
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Detection of Circulating Tumor Cells in Metastatic and Clinically Localized Urothelial CarcinomaUrology, 2011
- Microchip-based immunomagnetic detection of circulating tumor cellsLab on a Chip, 2011
- Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinomaJournal of Cancer Research and Clinical Oncology, 2011
- Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapyJournal of Cancer Research and Clinical Oncology, 2010
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007